TG Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	700.35	616.29	329	233.66	2.79	6.69
Revenue Growth	81.26%	87.32%	40.80%	8290.02%	-58.36%	4300.66%
Cost of Revenue	118.68	100.71	38.49	14.13	0.27	0.79
Gross Profit	581.67	515.57	290.52	219.53	2.52	5.9
Selling, General & Admin	269.92	232.03	154.3	122.71	95.48	128.09
Research & Development	162.25	160.22	94.29	76.19	125.35	222.58
Total Operating Expenses	432.17	392.25	248.59	198.9	220.84	350.67
Operating Income	149.5	123.32	41.93	20.63	-218.32	-344.77
Interest Expense	-27.64	-26.73	-24.03	-12.62	-10.19	-5.64
Other Non-Operating Income (Expense)	0.42	10.79	7.69	5.04	4.7	2.31
Total Non-Operating Income (Expense)	-27.21	-15.93	-16.34	-7.57	-5.5	-3.33
Pretax Income	122.29	107.39	25.59	13.06	-223.81	-348.1
Provision for Income Taxes	362.25	339.79	-2.21	-0.39	-	-
Net Income	461.9	447.18	23.38	12.67	-223.81	-348.1
Net Income to Common	461.9	447.18	23.38	12.67	-223.81	-348.1
Net Income Growth	1079.81%	1812.41%	84.52%	-	-	-
Shares Outstanding (Basic)	145	144	145	142	135	132
Shares Outstanding (Diluted)	161	161	160	149	135	132
Shares Change	-0.03%	0.67%	7.96%	9.67%	2.41%	14.64%
EPS (Basic)	3.18	3.10	0.16	0.09	-1.65	-2.63
EPS (Diluted)	2.86	2.77	0.15	0.09	-1.65	-2.63
EPS Growth	1091.67%	1746.67%	66.67%	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-14.19	-24.99	-40.56	-31.41	-176.18	-296.04
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.09	-0.15	-0.25	-0.21	-1.30	-2.24
Gross Margin	83.05%	83.66%	88.30%	93.95%	90.48%	88.19%
Operating Margin	21.35%	20.01%	12.74%	8.83%	-7838.99%	-5154.28%
Profit Margin	65.95%	72.56%	7.11%	5.42%	-8036.34%	-5204.08%
FCF Margin	-2.03%	-4.05%	-12.33%	-13.44%	-6326.18%	-4425.70%
EBITDA	149.58	123.38	42	20.84	-218.01	-344.49
EBITDA Margin	21.36%	20.02%	12.76%	8.92%	-7828.11%	-5150.07%
EBIT	149.5	123.32	41.93	20.63	-218.32	-344.77
EBIT Margin	21.35%	20.01%	12.74%	8.83%	-7838.99%	-5154.28%
Effective Tax Rate	296.24%	316.41%	-8.64%	-2.99%	0.00%	0.00%

SEC Filings: 10-K · 10-Q